Cellebrite DI Ltd.

NasdaqGS:CLBT Lagerbericht

Marktkapitalisierung: US$3.2b

Cellebrite DI Management

Management Kriterienprüfungen 2/4

Cellebrite DI CEO ist Tom Hogan , ernannt in Dec 2024, hat eine Amtszeit von 1.33 Jahren. Die jährliche Gesamtvergütung beträgt $10.80M , bestehend aus 4.8% Gehalt und 95.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.28% der Aktien des Unternehmens, im Wert von $8.82M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.3 Jahre bzw. 4.7 Jahre.

Wichtige Informationen

Tom Hogan

Geschäftsführender

US$10.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts4.82%
Amtszeit als Geschäftsführer1.3yrs
Eigentum des Geschäftsführers0.3%
Durchschnittliche Amtszeit des Managements1.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder4.7yrs

Jüngste Management Updates

Recent updates

CLBT: Updated Risk Profile And 2026 Guidance Will Support Premium P/E Potential

Analysts have trimmed their price targets on Cellebrite DI by $2. This reflects updated views on the stock's risk profile and valuation assumptions, while core growth and margin expectations remain largely unchanged.

CLBT: Updated Modeling And 2026 Guidance Will Support Premium P/E Potential

Cellebrite DI's analyst price targets have been trimmed by $2, with analysts linking the adjustment to updated assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts trimming their price targets by $2 are tying the move to refreshed views on discount rates, long term revenue growth, profit margins, and future P/E assumptions, rather than a single company specific event.

Cellebrite: A Rare SaaS Play Where AI Is A Tailwind, Not A Threat

Apr 06

CLBT: Refined Modeling And 2026 Guidance Will Support Premium P/E Potential

Analysts trimmed their price targets for Cellebrite DI by $2 to $21.67, citing updated assumptions on discount rate, long term revenue growth, profit margin and future P/E. These changes keep fair value broadly unchanged while slightly adjusting the risk and return profile.

CLBT: 2026 Revenue Guidance Will Support Earnings Power Despite P/E Recalibration

Analysts have trimmed their price targets on Cellebrite DI by $2, reflecting updated views on the stock's future P/E multiple and risk profile, while keeping key growth and profitability assumptions largely unchanged. Analyst Commentary Recent research updates suggest that analysts are adjusting their views on Cellebrite DI more around valuation mechanics than around its underlying business assumptions.

CLBT: Sustained Margins And 2026 Guidance Will Support Earnings Power

Analysts have adjusted their average price target on Cellebrite DI to about $21.67, down from the previous $24.71 level. The revised target reflects updated views on fair value, profit margins and future P/E assumptions following recent research updates from multiple firms.

CLBT: Higher Profitability Assumptions Will Support Stronger Medium Term Earnings Power

Analysts have raised their price target on Cellebrite DI from US$18.00 to US$23.00, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E as the key drivers of the change. What's in the News Cellebrite DI issued earnings guidance for the fourth quarter of 2025, with expected revenue between US$123 million and US$128 million and annual growth guidance of 13% to 17% (company guidance).

CLBT: Sustained Margins And 2025 ARR Guidance Will Support Earnings Power

Analysts have maintained their price target on Cellebrite DI at US$24.71, with only minor tweaks to inputs such as the discount rate and forward P/E, reflecting stable expectations around revenue growth and profit margin assumptions. What's in the News Cellebrite DI issued earnings guidance for the fourth quarter of 2025, targeting revenue of US$123 million to US$128 million, with annual growth of 13% to 17% (company guidance).

Cellebrite DI Ltd.'s (NASDAQ:CLBT) Shareholders Might Be Looking For Exit

Jan 13
Cellebrite DI Ltd.'s (NASDAQ:CLBT) Shareholders Might Be Looking For Exit

CLBT: Sustained Margin Strength Will Support Future Earnings Power

Analysts have maintained their fair value estimate for Cellebrite DI at US$24.71, making only minor adjustments to inputs such as the discount rate and long term P/E assumptions. This reflects a view that recent information does not materially alter their price outlook.

CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead

Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, citing incremental improvements in the company’s discount rate assumptions and sustained expectations for high revenue growth and robust profit margins. What's in the News Cellebrite DI issued fourth quarter 2025 revenue guidance of $123 million to $128 million, implying year over year growth of 13% to 17% (company guidance).

CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead

Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, reflecting slightly higher long term revenue growth and profit margin expectations that more than offset a marginally higher assumed discount rate and a modestly lower future P/E multiple. What's in the News Cellebrite DI issued revenue guidance for the fourth quarter of 2025, projecting between $123 million and $128 million, representing annual growth of 13% to 17% (company guidance).

CLBT: Profit Margins Will Drive Improved Earnings Outlook Into Next Year

Analysts have raised their price target for Cellebrite DI from $23.14 to $24.71. This change reflects increased confidence in the company’s stronger profit margins and revenue growth outlook.

Cloud SaaS Solutions Will Drive Digital Forensics Adoption

Cellebrite DI’s consensus price target was modestly raised to $23.14 as analysts anticipate near-term revenue softness due to U.S. federal budget constraints and delayed deal timing, while seeing future upside from eventual deal catch-up and FedRAMP progress. Analyst Commentary Slower-moving Q1 deals in Europe were completed in Q2, but persistent softness in U.S. federal deals is expected to continue until at least October, impacting near-term revenue.

What Cellebrite DI Ltd.'s (NASDAQ:CLBT) 26% Share Price Gain Is Not Telling You

Sep 09
What Cellebrite DI Ltd.'s (NASDAQ:CLBT) 26% Share Price Gain Is Not Telling You

Earnings Beat: Cellebrite DI Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 18
Earnings Beat: Cellebrite DI Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Cloud SaaS Solutions Will Drive Digital Forensics Adoption

Cellebrite DI’s consensus price target held steady at $23.00 as analysts factor in near-term headwinds from delayed federal spending and efficiency impacts, yet remain positive about long-term growth driven by healthy demand and anticipated federal certifications. Analyst Commentary Lowered Q2 results and second half guidance due to ongoing efficiency impacts and customer budget pauses.
User avatar

Cloud-Ready AI And Inseyets Migration Will Expand Digital Capabilities

Shift to cloud-based AI platforms and expansion in digital investigations are set to boost revenue through subscription services and high-margin solutions.

Cellebrite DI: A Compounder But Not Yet Priced For Conviction Buy

Apr 24

Cellebrite DI Ltd. (NASDAQ:CLBT) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 16
Cellebrite DI Ltd. (NASDAQ:CLBT) Analysts Are Pretty Bullish On The Stock After Recent Results

Cellebrite DI: Attractive Company In Connection With AI And Digital Investigation

Feb 04

A Look At The Intrinsic Value Of Cellebrite DI Ltd. (NASDAQ:CLBT)

Jan 10
A Look At The Intrinsic Value Of Cellebrite DI Ltd. (NASDAQ:CLBT)

Cellebrite: There Are Potential Risks That Could Damper Growth

Nov 08

Is There Now An Opportunity In Cellebrite DI Ltd. (NASDAQ:CLBT)?

Oct 30
Is There Now An Opportunity In Cellebrite DI Ltd. (NASDAQ:CLBT)?

There Could Be A Chance Cellebrite DI Ltd.'s (NASDAQ:CLBT) CEO Will Have Their Compensation Increased

Sep 10
There Could Be A Chance Cellebrite DI Ltd.'s (NASDAQ:CLBT) CEO Will Have Their Compensation Increased

Cellebrite: Rating Downgrade As Valuation Has Caught Up

Aug 27

Cellebrite DI Ltd.'s (NASDAQ:CLBT) 29% Share Price Surge Not Quite Adding Up

Aug 17
Cellebrite DI Ltd.'s (NASDAQ:CLBT) 29% Share Price Surge Not Quite Adding Up

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Tom Hogan im Vergleich zu den Einnahmen von Cellebrite DI verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Dec 31 2025US$11mUS$520k

US$78m

Sep 30 2025n/an/a

US$76m

Jun 30 2025n/an/a

-US$151m

Mar 31 2025n/an/a

-US$194m

Dec 31 2024US$4mUS$150k

-US$283m

Vergütung im Vergleich zum Markt: TomDie Gesamtvergütung ($USD10.80M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD7.12M).

Entschädigung vs. Einkommen: TomDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Tom Hogan (66 yo)

1.3yrs
Amtszeit
US$10,798,000
Vergütung

Mr. Thomas E. Hogan, also known as Tom, has been Director of Cellebrite DI Ltd. since August 2023 and had been Executive Chairman since August 2023 until January 1, 2025 and serves as its Chief Executive O...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Thomas Hogan
CEO & Director1.3yrsUS$10.80m0.28%
$ 8.8m
David Barter
Chief Financial Officerless than a yearUS$1.89m0.15%
$ 4.8m
Ronnen Armon
Chief Products & Technologies Officerless than a yearUS$1.47m0.11%
$ 3.5m
Marcus Jewell
Global Chief Revenue Officer2.4yrsUS$2.38m0.18%
$ 5.8m
Christopher Wade
Chief Technology Officerless than a yearkeine Daten0.24%
$ 7.8m
Sigalit Shavit
Chief Information Officer1.7yrskeine Daten0.033%
$ 1.1m
Andrew Kramer
Vice President of Investor Relationsno datakeine Datenkeine Daten
Holly Windham
General Counsel & Chief Compliance Officerless than a yearkeine Daten0.038%
$ 1.2m
David Gee
Chief Marketing Officer2.1yrskeine Daten0.059%
$ 1.9m
Zohar Tadmor-Eilat
Chief People Officer3.3yrskeine Daten0.052%
$ 1.6m
1.3yrs
Durchschnittliche Betriebszugehörigkeit
57yo
Durchschnittliches Alter

Erfahrenes Management: CLBTDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.3 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Thomas Hogan
CEO & Director2.7yrsUS$10.80m0.28%
$ 8.8m
Michael Capellas
Lead Independent Director1.3yrskeine Daten0.0071%
$ 226.4k
Dafna Gruber
Independent External Director4.7yrskeine Daten0.011%
$ 354.8k
Adam Clammer
Independent Chairman4.7yrskeine Daten0.33%
$ 10.3m
Troy Richardson
Independent Director1.7yrskeine Daten0.0084%
$ 266.6k
Brandon Van Buren
Independent Director2.9yrskeine Daten0.014%
$ 451.8k
Nadine Baudot-Trajtenberg
Independent External Director4.7yrskeine Daten0.014%
$ 451.8k
Yonatan Domnitz
Independent Director6yrskeine Daten0.024%
$ 772.6k
Ryusuke Utsumi
Independent Director6yrskeine Daten0.016%
$ 518.4k
Koby Huberman
Advisory Board Memberno datakeine Datenkeine Daten
4.7yrs
Durchschnittliche Betriebszugehörigkeit
60yo
Durchschnittliches Alter

Erfahrener Vorstand: CLBTDie Vorstandsmitglieder gelten als erfahren (4.7 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/04/30 00:21
Aktienkurs zum Tagesende2026/04/30 00:00
Gewinne2025/12/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Cellebrite DI Ltd. wird von 9 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Tyler RadkeCitigroup Inc
Jeffrey Van RheeCraig-Hallum Capital Group LLC
Bhavin ShahDeutsche Bank